FindTrial
Sign In

Comparison of two biomarkers in blood( tissue inhibitor of metalloproteinase 1 and nucleosomes) to predict death rates in patients with severe infection.

Comparison of serum nucleosomes and Tissue Inhibitor of Metalloproteinase 1(TIMP1) in predicting mortality in adult critically ill patients in sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/013770
Enrollment
80
Registered
2018-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Critically ill Patients within 24 hours of development of sepsis or septic shock

Interventions

Control Intervention1: Serum Nucleosomes and Tissue Inhibitor of Metalloproteinase 1(TIMP1): Comparing the mortality predictive ability between serum nucleosomes and Tissue Inhibitor of Metalloprotein

Sponsors

Self
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient in Sepsis or septic shock on admission to ICU or who went into sepsis or septic shock in ICU will be included in this study.Once the patient is recruited into the study the following baseline characteristics will be recorded- demographic characteristics (age, gender, weight), primary diagnosis, source of infection, blood culture report (if available), day of ICU admission, day of inclusion into the study, Sequential Organ Failure Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation (APACHE II) score will be obtained within 24 h of admission. 10 ml of venous blood , either from percutaneous route or central line will be obtained within 24 hours of the patient in Sepsis or septic shock on admission to ICU or who went into sepsis or septic shock in ICU.The quantification of the nucleosomes and TIMP1 will be done using Enzyme linked immunosorbant assay ( ELISA) All the patients will be followed till discharge from ICU or death in ICU.

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1. Patients with advanced malignancy 2. Immunocompromised or transplant recipients 3. Radiation therapy 4. Coronary artery disease, Heart failure

Design outcomes

Primary

MeasureTime frame
Comparing predictability of nucleosomes and TIMP1 in estimating sepsis mortality.Timepoint: Till patient is discharged from ICU or death in ICU—

Secondary

MeasureTime frame
1. Evaluating the effects of circulatory levels of nucleosomes and TIMP1 in assessing disease severity and organ dysfunction.Timepoint: Sample will be taken once , within 24 hours of patient going into sepsis/septic shock.Patient will be followed till discharge/ death from ICU—

Countries

India

Contacts

Public ContactNITIN RAI

All India Institute of Medical Sciences, New Delhi

lokeshkashyap@yahoo.com8527613852

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026